LP352 for children and adults with DEE
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial tests a medication called LP352 for children and adults with certain types of epilepsy (Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathies). It's for people who already completed a previous study of LP352 and may benefit from continued treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous LP352 study (LP352-301 or LP352-302) up to Visit 8.
- You must have a diagnosis of Dravet syndrome, Lennox-Gastaut syndrome, or another developmental and epileptic encephalopathy.
- You must weigh at least 10 kg (about 22 pounds).
- You cannot be pregnant, breastfeeding, or planning to become pregnant.
- You cannot be at risk for suicidal behavior or have severe depression, anorexia, or bulimia.
- You cannot use cannabis products that are not approved or contain high THC.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a new, more detailed DNA test (long-read sequencing) to find the cause of severe epilepsy with developmental delays in children when standard genetic testing did not provide an answer. It aims to help families understand the genetic basis of their child's condition.
This study tests a new medicine called LP352 for children and adults with Dravet syndrome. It compares the study drug to a placebo (a pill with no medicine) to see if it helps reduce seizures.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This trial tests a new type of brain stimulation (adaptive deep brain stimulation) that adjusts in real time to stop seizures in children with Lennox-Gastaut syndrome. It's for children who haven't gotten enough help from medications and have frequent drop seizures.
This trial tests a new drug called BMB-101 for people with absence epilepsy (including Jeavons syndrome) or developmental epileptic encephalopathies (DEE) like Dravet or Lennox-Gastaut. It aims to see if the drug can reduce seizure frequency and is safe.
This study tests a new CBD oil (CBD-OS) to see if it safely reduces seizures in people with developmental and epileptic encephalopathy (DEE), a condition where both development and seizure control are affected. Participants must already be on a stable antiseizure treatment.
Hear when a new Developmental and Epileptic Encephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.